PTPN23-dependent activation of PI3KC2α is a therapeutic vulnerability of BRAF-mutant cancers
Journal of Experimental Medicine · 2025
DOI: 10.1084/jem.20241147 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Experimental Medicine, 2025. Verfasst von Ying He und 20 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Cancer Research, Shenzhen Bay Laboratory , Shenzhen, China. Hauptthemen laut MEDLINE: Melanoma, Mutation, Proto-Oncogene Proteins B-raf, Protein Tyrosine Phosphatases, Non-Receptor. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Key R&D Program of China, Shenzhen Medical Research Fund, National Natural Science Foundation of China.
Abstract (Originalsprache)
BRAF mutations drive initiation and progression of various tumors. While BRAF inhibitors are effective in BRAF-mutant melanoma patients, intrinsic or acquired resistance to these therapies is common. Here, we identify non–receptor-type protein tyrosine phosphatase 23 (PTPN23) as an alternative effective target in BRAF-mutant cancer cells. Silencing PTPN23 selectively kills BRAF-mutant melanoma cells but not those with wild-type BRAF. Mechanistically, PTPN23, a catalytically inactive phosphatase, intriguingly induces WNK3-mediated phosphorylation of phosphoinositide 3-kinase class II alpha (PI3KC2α) at serine 329, enhancing its catalytic activity. This activation promotes production of PI(3,4)P2 and subsequent AKT2 activation at endosomes to support cell survival. Genetic or pharmacological targeting of the PTPN23-PI3KC2α-AKT2 signaling axis, alone or in combination with BRAF inhibitors, effectively inhibits the growth of BRAF-mutant melanoma and other cancers in vitro and in vivo. We also demonstrate that melanocyte-specific knockout of PTPN23 significantly inhibits BRAFV600E-driven melanomagenesis. Altogether, our findings demonstrate that targeting PTPN23/PI3KC2α offers a new and viable therapeutic strategy for BRAF-mutant cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Cancer Research, Shenzhen Bay Laboratory , Shenzhen, China.
- Medical Research Institute, Guangdong Provincial People's Hospital, Southern Medical University , Guangzhou, China.
- Shenzhen Medical Academy of Research and Translation (SMART) , Shenzhen, China.
- School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School , Shenzhen, China.
- National Key Laboratory for Novel Software Technology, Nanjing University , Nanjing, China.
- School of Artificial Intelligence, Nanjing University , Nanjing, China.
ORCID-Profile: Ying He, Wei Li, Meiling Zhang, Hui Wang, Peilu Lin, Ying Yu, Bin Huang, Meng Hao, Jianuo He, Weiyao Kong, Dan Luo, Tengteng Xu, Jiaqi Wang, Ying Huang, Qinwen Zhao, Ying Liu, Jie Zhang, Yong Nian, Lei Zhang, Bo Zhu, Chengqian Yin
Förderung
- National Key R&D Program of China
- Shenzhen Medical Research Fund
- National Natural Science Foundation of China
- Shenzhen Bay Laboratory
Zitieren
APA
He, Y., Li, W., Zhang, M., Wang, H., Lin, P., Yu, Y., Huang, B., Hao, M., He, J., Kong, W., Luo, D., Xu, T., Wang, J., Huang, Y., Zhao, Q., Liu, Y., Zhang, J., Nian, Y., Zhang, L., …, & Yin, C. (2025). PTPN23-dependent activation of PI3KC2α is a therapeutic vulnerability of BRAF-mutant cancers. Journal of Experimental Medicine. https://doi.org/10.1084/jem.20241147
Vancouver
He Y, Li W, Zhang M, Wang H, Lin P, Yu Y, et al. PTPN23-dependent activation of PI3KC2α is a therapeutic vulnerability of BRAF-mutant cancers. Journal of Experimental Medicine. 2025. doi:10.1084/jem.20241147
BibTeX
@article{He2025,
author = {He, Ying and Li, Wei and Zhang, Meiling and Wang, Hui and Lin, Peilu and Yu, Ying and Huang, Bin and Hao, Meng and He, Jianuo and Kong, Weiyao and Luo, Dan and Xu, Tengteng and Wang, Jiaqi and Huang, Ying and Zhao, Qinwen and Liu, Ying and Zhang, Jie and Nian, Yong and Zhang, Lei and Zhu, Bo and Yin, Chengqian},
title = {PTPN23-dependent activation of PI3KC2α is a therapeutic vulnerability of BRAF-mutant cancers},
journal = {Journal of Experimental Medicine},
year = {2025},
doi = {10.1084/jem.20241147}
}
EUVIMED